# US 2008/0293797 A1 · Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0293797 A1
- Document ID: US20080293797A1
- Status: Published application
- Kind: A1
- Application number: 11/995,775
- Filed: 2006-07-17
- Published: 2008-11-27
- Earliest claimed: 2005-07-15
- Assignees: Laboratorios Del Dr. Esteve, S.A.
- Inventors: Antonio Torrens Jover; Susana Yenes Minguez
- Web page: https://patentgrep.com/patent/US20080293797A1

## CPC

- C07D 231/54: condensed with carbocyclic rings or ring systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/06: having one double bond between ring members or between a ring member and a non-ring member
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to Cycloalkane-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

## Claims

### Claim 1

Cycloalkane-substituted pyrazoline compounds of general formula I,
wherein
Z is selected from C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent phenyl, thienyl, naphtyl or pyridyl which groups may be substituted with 1, 2 or 3 substituents W, which can be the same or different, selected from the group
branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)-alkyl-heterocyclyl;
R8 representing Cycloalkyl—especially a C7-8-Cycloalkyl—unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
n being 0 or 1
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio;
in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 2 (depends on 1)

Cycloalkane-substituted pyrazoline compounds of general formulas Ia or Ib according to claim 1,
wherein
Z is selected from C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent phenyl, thienyl, naphtyl or pyridyl which groups may be substituted with 1, 2 or 3 substituents W, which can be the same or different, from the group:
branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)-alkyl-heterocyclyl;
R8 representing Cycloalkyl—especially a C7-8-Cycloalkyl—unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
n being 0 or 1
optionally in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 3 (depends on 1)

Cycloalkane-substituted pyrazoline compounds of general formula II according to claim 1,
wherein
Z′ is selected from C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated; preferably is either CH3 or C2H5;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)alkyl-heterocyclyl;
R18 representing a C7-8-Cycloalkyl, unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
m being 0 or 1
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio;
in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 4 (depends on 3)

Cycloalkane-substituted pyrazoline compounds of general formulas IIa and IIb according to claim 3,
wherein
Z′ is selected from C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated; preferably is either CH3 or C2H5;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, CHF2, CH2F, OCHF2, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)heterocyclyl or C(O)-alkyl-heterocyclyl;
R18 representing a C7-8-Cycloalkyl, unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
m being 0 or 1
optionally in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 5 (depends on 3)

Cycloalkane-substituted pyrazoline compounds according to claim 3, characterized in that
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2;
preferably
R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3.

### Claim 6 (depends on 3)

Cycloalkane-substituted pyrazoline compounds according to claim 3, characterized in that
substituents S′, which can be the same or different are selected from the group:
H, F, Cl, Br, I, OH, CH3, C2H5, OCH3, OCF3, or CF3.

### Claim 7 (depends on 1)

Cycloalkane-substituted pyrazoline compounds of general formula III according to claim 1,
wherein
Z″ is selected from CH3 or C2H5;
R21, R22, R23 and R24 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)-alkyl-heterocyclyl;
R28 representing a C7-8-Cycloalkyl, unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
p being 0 or 1
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio;
in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 8 (depends on 7)

Cycloalkane-substituted pyrazoline compounds of general formulas IIIa and IIIb according to claim 7,
wherein
Z″ is selected from CH3 or C2H5;
R21, R22, R23 and R24 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)-alkyl-heterocyclyl;
R28 representing a C7-8-Cycloalkyl, unsubstituted or at least monosubstituted with 1, 2 or 3 substituents S′, which can be the same or different, selected from the group:
H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
p being 0 or 1
optionally in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim 9 (depends on 7)

Cycloalkane-substituted pyrazoline compounds according to claim 7, characterized in that
R21 represents; O—P, with P denominating a prodrug group consisting of aryl, C8-20-alkyl, heterocyclyl, C(O)-aryl, C(O)-heterocyclyl, C(O)—C1-20-alkyl, while R22, R23 and R24 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2;
preferably
R21 represents; O—P, with P denominating a prodrug group consisting of aryl, C8-20-alkyl, heterocyclyl, C(O)-aryl, C(O)-heterocyclyl, C(O)—C1-20-alkyl, while R22, R23 and R24 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3;
most preferably
R21 represents; O—P, with P denominating a prodrug group consisting of aryl, C8-20-alkyl, heterocyclyl, C(O)-aryl, C(O)-heterocyclyl, C(O)—C1-20-alkyl, while R22, R23 and R24 independently of one another represent OH, OCH3, F, Cl, Br, I or OCF3.

### Claim 10 (depends on 7)

Cycloalkane-substituted pyrazoline compounds according to claim 7, characterized in that
R21, R22, R23 and R24 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2;
preferably
R21, R22, R23 and R24 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3;
most preferably
R21 represents H, while R22, R23 and R24 independently of one another represent OH, OCH3, F, Cl, Br, I or OCF3.

### Claim 11 (depends on 7)

Cycloalkane-substituted pyrazoline compounds according to claim 7, characterized in that
substituents S′, which can be the same or different are selected from the group:
H, F, Cl, Br, I, OH, CH3, C2H5, OCH3, OCF3, or CF3.

### Claim 12 (depends on 7)

Cycloalkane-substituted pyrazoline compounds of general formulas IV, IVa or IVb according to claim 7,
wherein
Z′″ is selected from CH3 or C2H5;
R31, R32, R33 and R34 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O—P, with P denominating a prodrug group consisting of substituted or unsubstituted, branched or linear, saturated or unsaturated C8-20-alkyl or C(O)—C1-20-alkyl; substituted or unsubstituted aryl, alkyl-aryl, heterocyclyl or alkyl-heterocyclyl; substituted or unsubstituted C(O)-aryl, C(O)-alkyl-aryl, C(O)-heterocyclyl or C(O)-alkyl-heterocyclyl;
R35, R36 and R37 are independently from one another selected from, H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
optionally in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

### Claim at position 13

13-16. (canceled)

### Claim 17 (depends on 1)

Process for the manufacture of substituted pyrazoline compounds of general formula I according to claim 1, characterized in that at least one benzaldehyde compound of general formula V
wherein X has the meaning according to claim 1, is reacted with a pyruvate compound of general formula (VI)
wherein Z has the meaning according to claim 1; G represents an OR group with R being H or a branched or unbranched C1-6 alkyl radical or G represents an O−K group with K being a cation, to yield a compound of general formula (VII)
wherein X and Z have the meaning given above, which is optionally isolated and/or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of general formula (VIII)
or a corresponding salt thereof, wherein Y has the meaning according to claim 1, under inert atmosphere, to yield a compound of general formula (IX)
wherein X, Z and Y have the meaning as given above, which is optionally isolated and/or optionally purified, and optionally transferred under inert atmosphere to a compound of general formula (XI) via the reaction with an activating agent
wherein the substituents X, Z and Y have the meaning given above and A represents a leaving group, said compound being optionally isolated and/or optionally purified, and at least one compound of general formula (XI) is reacted with a compound of general formula XII
wherein n and R8 are defined as in claim 1; under inert atmosphere to yield a substituted pyrazoline compound of general formula I, which is optionally isolated and/or optionally purified.

### Claim 18 (depends on 1)

Medicament comprising at least one substituted pyrazoline compound of general formula I according to claim 1, and optionally one or more pharmaceutically acceptable excipients.

### Claim 19 (depends on 1)

A method for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB1) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders, the method comprising administering to a patient a compound of claim 1.

### Claim 20 (depends on 1)

A method for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insulin dependent diabetes mellitus), more preferably obesity, the method comprising administering to a patient a compound of claim 1.

### Claim 21 (depends on 1)

A method for the prophylaxis and/or treatment of psychosis, the method comprising administering to a patient a compound of claim 1.

### Claim 22 (depends on 1)

A method for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction and/or nicotine abuse and/or nicotine addiction, the method comprising administering to a patient a compound of claim 1.

### Claim 23 (depends on 1)

A method for the prophylaxis and/or treatment of cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer, the method comprising administering to a patient a compound of claim 1.

### Claim 24 (depends on 1)

A method for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer-associated bone disease or Paget's disease of bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, head trauma, stroke, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit, the method comprising administering to a patient a compound of claim 1.

### Claim at position 22

25-28. (canceled)
